- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04809363
Studie CDPATH™, která pomáhá zvládat a léčit Crohnovu chorobu (COMPASS-CD)
Studie fáze 4 hodnotící použití CDPATH™ v reálném světě, nástroje pro predikci rizika Crohnovy choroby
CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.
Přehled studie
Detailní popis
The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.
The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.
This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 4
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85032
- Arizona Arthritis & Rheumatology Research, PLLC
-
-
California
-
Loma Linda, California, Spojené státy, 92357
- VA Loma Linda Healthcare System
-
Murrieta, California, Spojené státy, 92563
- United Medical Doctors
-
Newport Beach, California, Spojené státy, 92663
- University of Southern California Medical Center
-
Orange, California, Spojené státy, 92868
- University of California at Irvine Medical Center
-
Orange, California, Spojené státy, 92868
- Clinnova Research Solutions
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80014
- Kaiser Permanate of Colorado
-
-
Connecticut
-
Hamden, Connecticut, Spojené státy, 06518
- Medical Research Center of Connecticut, LLC
-
-
Florida
-
Clearwater, Florida, Spojené státy, 33762
- West Central Gastroenterology d/b/a Gastro Florida
-
Pensacola, Florida, Spojené státy, 32503
- Gastroenterology Associates of Pensacola, PA
-
-
Idaho
-
Idaho Falls, Idaho, Spojené státy, 83404
- Grand Teton Research Group, PLL
-
-
Illinois
-
Arlington Heights, Illinois, Spojené státy, 60005
- GI Alliance
-
Gurnee, Illinois, Spojené státy, 60031
- GI Alliance
-
Northbrook, Illinois, Spojené státy, 60062
- Comprehensive Gastrointestinal Health
-
Rockford, Illinois, Spojené státy, 61107
- Rockford Gastroenterology Associates, Ltd.
-
-
Indiana
-
Indianapolis, Indiana, Spojené státy, 46202
- Indiana University
-
-
Iowa
-
Clive, Iowa, Spojené státy, 50325
- Iowa Digestive Disease Center
-
Iowa City, Iowa, Spojené státy, 52242-1009
- University of Iowa Hospitals & Clinics
-
-
Kansas
-
Kansas City, Kansas, Spojené státy, 66160
- University of Kansas Medical Center Research Institute, Inc.
-
-
Louisiana
-
Baton Rouge, Louisiana, Spojené státy, 70809
- GI Alliance - Baton Rouge
-
Shreveport, Louisiana, Spojené státy, 71105
- Louisiana Research Center, LLC
-
-
Maryland
-
Columbia, Maryland, Spojené státy, 21045
- Gastro Center of Maryland
-
-
Massachusetts
-
Burlington, Massachusetts, Spojené státy, 01805
- Lahey Clinic Inc. - PARENT ACCOUNT
-
Worcester, Massachusetts, Spojené státy, 01655
- UMASS Memorial Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87131-0001
- University of New Mexico
-
-
New York
-
New York, New York, Spojené státy, 10075-1850
- Lenox Hill Hospital
-
-
Ohio
-
Beavercreek, Ohio, Spojené státy, 45431
- Clinical Inquest Center Ltd
-
Dayton, Ohio, Spojené státy, 45415
- Dayton Gastroenterology, Inc
-
-
Oregon
-
Portland, Oregon, Spojené státy, 97220-9442
- The Oregon Clinic, P.C.
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Spojené státy, 17011
- Susquehanna Research Group, LLC
-
Pittsburgh, Pennsylvania, Spojené státy, 15213
- University of Pittsburgh Medical Center Health System
-
Pittsburgh, Pennsylvania, Spojené státy, 15212
- Allegheny Center for Digestive Health
-
Uniontown, Pennsylvania, Spojené státy, 15401
- Frontier Clinical Research, LLC
-
-
South Carolina
-
Summerville, South Carolina, Spojené státy, 29486
- Palmetto Primary Care Physician Division of Gastroenterology
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Medical Center, LLC
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37204
- Vanderbilt University Medical Center
-
-
Texas
-
Austin, Texas, Spojené státy, 78712
- The University of Texas at Austin
-
Houston, Texas, Spojené státy, 77030
- Baylor College of Medicine
-
Southlake, Texas, Spojené státy, 76092
- GI Alliance - Southlake
-
-
Utah
-
Ogden, Utah, Spojené státy, 84403
- Care Access Research Berkley
-
Salt Lake City, Utah, Spojené státy, 84132
- University of Utah
-
-
Virginia
-
Fairfax, Virginia, Spojené státy, 22031
- GCGA Physicians LLC
-
Lynchburg, Virginia, Spojené státy, 24502
- Gastroenterology Associates
-
-
Washington
-
Bellevue, Washington, Spojené státy, 98405
- GI Alliance
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
- Has agreed to use the CDPATH™ tool.
- Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.
Exclusion Criteria:
- Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
- Has had any non-CD-related abdominal surgery.
- Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
- Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Diagnostický
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: CDPATH™
Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis. |
Crohn's disease risk prediction tool.
Ostatní jména:
Three blood samples will be drawn. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Časové okno: Baseline (Day 1)
|
The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years. |
Baseline (Day 1)
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Časové okno: Up to 36 months
|
Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification. |
Up to 36 months
|
|
Change From Baseline in Decisional Conflict Scale (DCS) Score
Časové okno: Baseline, then every 6 months up to 36 months
|
DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict. |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Časové okno: Baseline, then every 6 months up to 36 months
|
WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity). |
Baseline, then every 6 months up to 36 months
|
|
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Časové okno: Baseline, then every 6 months up to 36 months
|
PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health). |
Baseline, then every 6 months up to 36 months
|
|
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Časové okno: Up to 36 months
|
Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool. |
Up to 36 months
|
|
Number of Participants with Clinical Outcomes
Časové okno: Up to 36 months
|
Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported. |
Up to 36 months
|
|
Percentage of Participants with Healthcare Resource Utilization
Časové okno: Up to 36 months
|
Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.). |
Up to 36 months
|
|
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Časové okno: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability. |
First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Study Director, Takeda
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- Vedolizumab-4015
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Kritéria přístupu pro sdílení IPD
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
- MÍZA
- ICF
- CSR
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .